- Home
- SAFE vs XERS Comparison
SAFE vs XERS Comparison
Compare SAFE & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | XERS |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SAFE | XERS |
|---|---|---|
| Price | $15.76 | $6.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $18.82 | $10.83 |
| AVG Volume (30 Days) | 335.5K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | 7.43 | ★ 100.00 |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $385,552,000.00 | $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | $4.31 | $22.86 |
| P/E Ratio | $10.00 | ★ N/A |
| Revenue Growth | 5.43 | ★ 142.67 |
| 52 Week Low | $12.76 | $4.26 |
| 52 Week High | $17.16 | $10.08 |
Technical Indicators
Market Signals| Indicator | SAFE | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 65.63 | 50.19 |
| Support Level | $15.73 | $5.79 |
| Resistance Level | $16.57 | $6.41 |
| Average True Range (ATR) | 0.36 | 0.21 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 74.27 | 38.77 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.